Allogene Therapeutics, Inc. Financial and Nonfinancial Liabilities, Fair Value Disclosure
Allogene Therapeutics, Inc. (ALLO) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $0 as of 2024-12-31, per its 10-K filed 2025-03-13.
Financial Statements › Notes
us-gaap:LiabilitiesFairValueDisclosure · last filed 2025-03-13
- 2024-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2023-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2022-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
- 2021-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $0.00.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-13 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-03-14 |
| 2021-12-31 | $0.00 10-K/A · filed 2024-03-14 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |